Similar renoprotection after renin-angiotensin-dependent and -independent antihypertensive therapy in 5/6-nephrectomized Ren-2 transgenic rats: are there blood pressure-independent effects?
Jazyk angličtina Země Austrálie Médium print
Typ dokumentu časopisecké články, práce podpořená grantem
- MeSH
- aldosteron moč MeSH
- angiotensin II krev metabolismus MeSH
- antihypertenziva farmakologie MeSH
- blokátory receptorů AT1 pro angiotensin II farmakologie MeSH
- chronické selhání ledvin farmakoterapie metabolismus prevence a kontrola MeSH
- diabetické nefropatie farmakoterapie prevence a kontrola MeSH
- diuretika farmakologie MeSH
- furosemid farmakologie MeSH
- hydrochlorthiazid farmakologie MeSH
- hypertenze farmakoterapie metabolismus MeSH
- indoly farmakologie MeSH
- inhibitory ACE farmakologie MeSH
- kardiomegalie farmakoterapie prevence a kontrola MeSH
- kombinovaná farmakoterapie MeSH
- kreatinin krev metabolismus moč MeSH
- krevní tlak účinky léků MeSH
- krysa rodu Rattus MeSH
- labetalol farmakologie MeSH
- losartan farmakologie MeSH
- potkani Sprague-Dawley MeSH
- potkani transgenní MeSH
- proteinurie krev metabolismus moč MeSH
- renin-angiotensin systém účinky léků MeSH
- renin metabolismus MeSH
- zvířata MeSH
- Check Tag
- krysa rodu Rattus MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Názvy látek
- aldosteron MeSH
- angiotensin II MeSH
- antihypertenziva MeSH
- blokátory receptorů AT1 pro angiotensin II MeSH
- diuretika MeSH
- furosemid MeSH
- hydrochlorthiazid MeSH
- indoly MeSH
- inhibitory ACE MeSH
- kreatinin MeSH
- labetalol MeSH
- losartan MeSH
- renin MeSH
- trandolapril MeSH Prohlížeč
1. Hypertension plays a critical role in the progression of chronic kidney disease (CKD) to end-stage renal disease (ESRD), but it has also been postulated that antihypertensive drugs that block the renin-angiotensin system (RAS) show class-specific renoprotective actions beyond their blood pressure (BP)-lowering effects. 2. Because this notion has recently been questioned, in the present study we compared the effects of a RAS-dependent antihypertensive therapy (a combination of trandolapril, an angiotensin-converting enzyme inhibitor (ACEI) and losartan, an angiotensin-II (AngII) receptor subtype 1A receptor antagonist) with a 'RAS-independent' antihypertensive therapy (a combination of labetalol, an alfa- and beta-adrenoreceptor antagonist with the diuretics, hydrochlorothiazide and furosemide) on the progression of CKD after 5/6 renal ablation (5/6 NX) in Ren-2 renin transgenic rats (TGR), a model of AngII-dependent hypertension. Normotensive transgene-negative Hannover Sprague-Dawley (HanSD) rats after 5/6 NX served as controls. 3. RAS-dependent and -independent antihypertensive therapies normalized BP and survival rate, and prevented the development of cardiac hypertrophy and glomerulosclerosis to the same degree in 5/6 NX HanSD rats and in 5/6 NX TGR. The present findings show that renoprotection, at least in rats after 5/6 NX, is predominantly BP-dependent. When equal lowering of BP was achieved, leading to normotension, cardio- and renoprotective effects were equivalent irrespective of the type of antihypertensive therapy. 4. These findings should be taken into consideration in attempts to develop new therapeutic approaches and strategies aimed to prevent the progression of CKD and to lower the incidence of ESRD.
Citace poskytuje Crossref.org
Empagliflozin Is Not Renoprotective in Non-Diabetic Rat Models of Chronic Kidney Disease
